chufangao/CTO huggingface dataset:
Clinical trial NCT02422290: Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)
Official title: Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)
Sponsor: New York State Psychiatric Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-03-31
Primary completion date: 2018-02-21
Completion date: 2020-07-31
Plan to share individual participant data: NO
Clinical trial NCT00630565: Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
Official title: Autologous Peripheral Blood Stem Cell Transplant for Acute Non-Lymphocytic Leukemia (ANLL)
Sponsor: Masonic Cancer Center, University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Slow Accrual
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2006-07-26
Primary completion date: 2022-07-28
Completion date: 2022-07-28
Baseline population: No participants enrolled under the age of 2 years old.
Clinical trial NCT02576509: An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
Official title: A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 743.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-12-07
Primary completion date: 2019-05-30
Completion date: 2024-02-07
Clinical trial NCT04782609: Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
Official title: A Phase 1b Dose Escalation/Dose Expansion Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
Acronym: Glio
Sponsor: Samus Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Samus Therapeutics Company Closure
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-27
Primary completion date: 2022-11-04
Completion date: 2022-11-04
Plan to share individual participant data: NO
Clinical trial NCT04770532: A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
Official title: A 26-week Trial Comparing the Effect and Safety of Once Weekly Insulin Icodec and Once Daily Insulin Degludec, Both With or Without Non-insulin Anti-diabetic Drugs, in Subjects With Type 2 Diabetes Treated With Basal Insulin
Acronym: ONWARDS 2
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 526.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-05
Primary completion date: 2022-01-27
Completion date: 2022-03-01
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT04871737: Study of a Live rNDV Based Vaccine Against COVID-19
Official title: Dose-escalation, Open-label, Non-randomized Phase I Study to Evaluate the Safety and Immunogenicity of Three Concentrations of a rNDV Vaccine Against SARS-CoV-2 Administered by the Intranasal and Intramuscular Route to Healthy Volunteers
Sponsor: Laboratorio Avi-Mex, S.A. de C.V. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 91.0 (ACTUAL)
Number of arms: 10.0
Start date: 2021-05-20
Primary completion date: 2022-08-21
Completion date: 2022-09-30
Plan to share individual participant data: NO
Clinical trial NCT04349072: A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
Official title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy
Acronym: VALOR-HCM
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 112.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-06
Primary completion date: 2022-02-07
Completion date: 2024-05-20
Clinical trial NCT04504734: Bucillamine in Treatment of Patients With COVID-19
Official title: Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19
Sponsor: Revive Therapeutics, Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Met definition of futility according to DSMB
Enrollment: 713.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-11-27
Primary completion date: 2023-06-12
Completion date: 2023-06-12
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04000009: Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Official title: A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Sponsor: ACADIA Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was terminated for business reasons and not due to safety concerns.
Enrollment: 235.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-06
Primary completion date: 2021-02-22
Completion date: 2021-02-22
Baseline population: All patients enrolled who received at least one dose of study medication
Limitations and caveats: This study was terminated early by the Sponsor for business reasons due to the COVID-19 pandemic; there were no safety concerns contributing to study termination. Patients were discontinued from the study and completed safety follow-up procedures.
Plan to share individual participant data: NO
Clinical trial NCT04604184: ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19
Official title: BI 764198 Efficacy and Safety in Prevention/Progression of ARDS and ARDS-related Complications Secondary to COVID-19 (ACTION ON COVID-19)
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Company decision
Enrollment: 133.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-03
Primary completion date: 2021-03-24
Completion date: 2021-05-31
Baseline population: Full Analysis Set (FAS): FAS included all patients (pts) in randomized set (RS) who received at least 1 dose of trial drug, comprised 129 pts (85.4%). Of all pts randomised, number (%) of pts not treated was similar in BI 764198 (2/67 pts \[3.0%\]) and placebo group (2/66 pts \[3.0%\]). The 4 pts excluded from FAS discontinued trial before receiving treatment for following reasons: pt's withdrawal (n=2), meeting an exclusion criterion (n=1), and clinical worsening (n=1).
Limitations and caveats: This trial was terminated early following the recommendation of a Data Monitoring Committee.
Plan to share individual participant data: YES
IPD sharing description: After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed Document Sharing Agreement.~Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.~The data shared are the raw clinical study data sets.
IPD time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
IPD access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Clinical trial NCT05445128: Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
Official title: A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of MGTA-145 in Combination With Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients With Sickle Cell Disease
Sponsor: Ensoma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: This study was voluntarily terminated due to a business decision not to proceed, and not due to any safety issue.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-24
Primary completion date: 2022-12-08
Completion date: 2023-02-02
Plan to share individual participant data: NO
Clinical trial NCT04085575: Efficacy of Intra-auricular Tranexamic Acid in Total Knee Arthroplasty
Official title: Efficacy of 1g Versus 2g Intra-auricular Tranexamic Acid in Postoperative Bleeding After Total Knee Arthroplasty
Sponsor: Centre Hospitalier de Montauban (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 100.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-01
Primary completion date: 2019-12-09
Completion date: 2020-01-09
Plan to share individual participant data: NO
IPD sharing description: The aim of our study was to observe postoperative bleeding with combined intravenous and per - os administration with two intra - articular doses (1 g and 2 g) of tranexamic acid.
Clinical trial NCT02564263: Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
Official title: A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 628.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-12-01
Primary completion date: 2018-10-15
Completion date: 2022-03-14
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03481894: Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age
Official title: Prospective, Randomized, Open-Label, Parallel-Group, Active-Controlled, Multicenter Study to Assess Safe and Effective Doses of Kabiven® in Pediatric Patients 2 to 16 Years of Age
Sponsor: Fresenius Kabi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: FDA released Fresenius Kabi from this post marketing requirement on 07/16/2019.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-31
Primary completion date: 2020-03-31
Completion date: 2021-03-31
Clinical trial NCT04172363: Clinical Relevance of the Antimicrobial Resistance Testing in the Treatment of Chronic Wounds With Antiseptics
Official title: Clinical Relevance of the Antimicrobial Resistance Testing in the Treatment of Chronic Wounds With Antiseptics
Acronym: AntiSeptic
Sponsor: RWTH Aachen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: PI left site
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-22
Primary completion date: 2021-05-22
Completion date: 2021-05-22
Plan to share individual participant data: NO
Clinical trial NCT04193566: Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes
Official title: Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes
Acronym: Astronaut
Sponsor: Steno Diabetes Center Copenhagen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-01
Primary completion date: 2020-09-01
Completion date: 2021-01-01
Plan to share individual participant data: NO
Clinical trial NCT03040999: Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
Official title: A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 804.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-04-05
Primary completion date: 2022-05-31
Completion date: 2024-08-21
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03973177: Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain
Official title: Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain Following Total Knee Arthroplasty: a Pilot Prospective, Randomized, Crossover Trial
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Covid restrictions on recruitment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-24
Primary completion date: 2022-07-31
Completion date: 2023-03-31
Plan to share individual participant data: NO
Clinical trial NCT04615949: Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Official title: Study to Evaluate the Efficacy and Safety of CardiolRx™ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial
Sponsor: Cardiol Therapeutics Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: The changing nature of COVID-19 including a more vaccinated population, increasing natural population immunity, milder variants and other related factors has meant that it is no longer realistic to recruit the patients in a reasonable time frame.
Enrollment: 90.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-30
Primary completion date: 2022-11-30
Completion date: 2022-11-30
Plan to share individual participant data: YES
IPD sharing description: The data will become available once the study has been published
IPD time frame: Data will become available in Q4 2022
IPD access criteria: Access to the journal in which article has been published
Clinical trial NCT02927847: Neuroimaging Reward, Behavioral Treatment, and Smoking Cessation
Official title: Targeting Reward Dysfunction as a Mechanism to Improve Smoking Cessation
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 35.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-02-01
Primary completion date: 2021-05-28
Completion date: 2022-05-27
Plan to share individual participant data: NO
Clinical trial NCT03253796: Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)
Official title: A Phase-IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Golimumab (MK-8259 [SCH 900259]) After Treatment Withdrawal, Compared With Continued Treatment (Either Full- or Reduced-Treatment Regimen), In Subjects With Non-Radiographic Axial Spondyloarthritis
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 323.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-11-07
Primary completion date: 2021-03-17
Completion date: 2021-03-17
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT02570503: Postoperative Pain Control After Periarticular Injection During Total Knee Arthroplasty
Official title: Do Intraoperative Periarticular Injections Improve Postoperative Pain Control in Patients Receiving Duramorph (Preservative Free) During Total Knee Arthroplasty? A Prospective, Double-Blind, Randomized Controlled Trial
Sponsor: Virginia Commonwealth University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study's primary aims are no longer clinically impactful, as intrathecal morphine has fallen out of favor and replaced with different agents so that outpatient/23 hr surgery is more predictably achievable.
Enrollment: 64.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-10-31
Primary completion date: 2021-02-11
Completion date: 2021-02-11
Plan to share individual participant data: NO
Clinical trial NCT04387448: A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
Official title: A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
Sponsor: Goldfinch Bio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 96.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-28
Primary completion date: 2022-11-01
Completion date: 2022-11-01
Plan to share individual participant data: NO
Clinical trial NCT04044430: Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
Official title: Phase I/II Trial of Encorafenib, Binimetinib, and Nivolumab in Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor funding
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-31
Primary completion date: 2022-07-31
Completion date: 2022-07-31
Plan to share individual participant data: NO
Clinical trial NCT03197064: Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia
Official title: Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-01-01
Primary completion date: 2020-01-31
Completion date: 2020-01-31
Plan to share individual participant data: YES
IPD sharing description: There is a plan to make IPD available only to members of the research team involved in this project. All patient identifying information will be removed from all data as it is collected to protect patient privacy.
Clinical trial NCT00948675: Study of Participants With Advanced Non-Small Cell Lung Cancer
Official title: A Study of Pemetrexed Plus Carboplatin Followed by Maintenance Pemetrexed vs Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced NCSLC of Nonsquamous Histology
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 361.0 (ACTUAL)
Number of arms: 2.0
Start date: 2009-09-01
Primary completion date: 2013-01-31
Completion date: 2020-11-06
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03316729: DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
Official title: Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects With Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
Sponsor: Daiichi Sankyo (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Product development cancelled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-31
Primary completion date: 2020-02-29
Completion date: 2020-02-29
Plan to share individual participant data: YES
IPD sharing description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Clinical trial NCT05760703: Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
Official title: Phase Ib/II: Multicenter, Open, Dose-escalation Evaluation of the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B Treated With Oral Antiviral Therapy(Long-term Follow-up)
Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The preliminary effectiveness data observed at present did not meet the expectations, the benefit of the subjects receiving the experimental drug was limited.
Enrollment: 9.0 (ACTUAL)
Number of arms: 4.0
Start date: 2023-04-25
Primary completion date: 2023-12-11
Completion date: 2023-12-11
Plan to share individual participant data: NO
Clinical trial NCT03552757: Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
Official title: Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity and Type 2 Diabetes
Acronym: STEP 2
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1210.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-06-04
Primary completion date: 2020-03-24
Completion date: 2020-05-01
Baseline population: Full analysis set (FAS) which comprised all randomised participants.
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com